Bone Biologics raises $3M, extends runway through Q2 2027

Filed July 23, 2026 · Period ending July 23, 2026 · ~1 min read

Key Changes

• high

  Completed $3M private placement with one institutional investor in July 2026; warrants could provide up to $6M more if exercised. Proceeds fund clinical trials, patent work, and general corporate purposes.

  Exhibit 99.1 view on EDGAR →
• high

  Management believes the financing extends operating runway through Q2 2027 without requiring near-term additional capital.

  Exhibit 99.1 view on EDGAR →
• medium

  Validated shelf life of rhNELL-1 protein extended to 29 months in May 2026, up from 24 months in December 2025, supporting manufacturing flexibility.

  Exhibit 99.1 view on EDGAR →